drughunter.com
< 1 minute read
Aug. 30, 2024

July 2024 Patents Searchable Table

Editor:  
Loading...

twitterlinkedinemail

Other articles you may be interested in

June 2024 Patent Highlights: GLP-1R Agonists, Polθ Inhibitors, Non-Ab PD-L1 Inhibitors, and More!

To help you quickly scan the patent literature, we’ve distilled down thousands of new documents into a searchable table of over 200 selected patents focused on key areas in drug discovery, all published in June 2024. This resource is enriched with detailed highlights on selected molecules targeting high-interest areas such as synthetically lethal Polθ inhibitors, SARM1 inhibitors for neurodegenerative indications, and our best guess at the identity of Gilead’s small molecule GLP-1R agonist GS-4571

May 2024 Patent Highlights: STING Antagonists, WIZ Degraders, Macrocyclic Amine-Based OX2R Modulators, and More

To help you quickly scan the patent literature, we’ve distilled down thousands of new documents into a searchable table of over 200 selected patents focused on key areas in drug discovery, all published in May 2024. This resource is enriched with detailed highlights on selected molecules targeting high-interest areas such as STING antagonists, WIZ degraders, RNA degraders, and macrocyclic amine-based OX2R modulators.

Highly Selective TREX1 Inhibitors from Constellation Pharmaceuticals

This article highlights a patent application from Constellation Pharmaceuticals that discloses the biological activity of compounds that act as TREX1 inhibitors, providing a summary of key data for selected molecules disclosed in the patent application.

How Might Puhe BioPharma’s WRN Helicase Inhibitors Differentiate from Novartis’?

This article highlights a patent application from Puhe BioPharma that discloses the biological activity of compounds that act as WRN helicase inhibitors, providing a summary of key data for selected molecules disclosed in the patent application.

March 2024 Patent Highlights: OX2R Agonists, TEAD Covalent Inhibitors, NaV1.8 Inhibitors, LRRK2 Inhibitors, and More

In March 2024, the landscape of patent disclosures continued to reflect the rapid pace of advances against key therapeutic targets. The Drug Hunter team has curated a searchable database encompassing over 200 patents pertinent to the field of drug discovery. This resource is further enriched with insightful spotlight on some of the most promising molecules and targets, including OX2R agonists, TEAD covalent inhibitors, NaV1.8 inhibitors, and selective PI3Kγ inhibitors, among others. This round-up provides a valuable tool for drug hunters to navigate the most recent trends in drug discovery.